Clinical trials
High Risk Prostate Cancer clinical trials
Below are recruiting high risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 348 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06257693RecruitingPhase 1
Prostate cancer implant trial before prostate removal surgery
This trial tests a new enzalutamide implant (Enolen) placed in the prostate before surgery to see if it helps treat early prostate cancer. It is for men who are already planning to have their prostate removed.
Chicago, IllinoisAges 21 years+ - NCT07364071RecruitingPhase 2
Hormone therapy and targeted radiation for high-risk prostate cancer
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
La Jolla, CaliforniaAges 18 years+ - NCT06238713Recruiting
New vs. standard robotic prostate surgery for early cancer
This study compares two ways of doing robot‑assisted prostate removal surgery. It aims to see if a newer, less invasive method through a single small cut is as safe and effective as the standard method. If you have early‑stage prostate cancer and are eligible, you could help improve surgical recovery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06558981RecruitingPhase 3
Radiation therapy after thyroid surgery for high-risk cancer
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
ShanghaiAges 14–80 - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+ - NCT07047495Recruiting
Personalized radiation therapy for early breast cancer
This trial is testing a way to personalize radiation therapy for people with early-stage breast cancer. It may help make treatment more precise and reduce side effects.
Milan, ItalyAges 18 years+ - NCT07293585RecruitingPhase 3
Precision radiation to protect erectile function in prostate cancer
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
Los Angeles, CaliforniaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT04831983Recruiting
Radiation treatment for intermediate- and high-risk prostate cancer
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
Monza, MBAges 18–90 - NCT07132073Enrolling by invitation
MRI-guided SBRT for high-risk prostate cancer
This study tests a precise radiation treatment for prostate cancer that uses MRI images to guide the radiation beams. It may be an option for men with higher-risk prostate cancer who can have an MRI and have not had radiation before.
Pamplona, Foral Community of NavarreAges 18–80 - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT06287541Recruiting
Do you need a second bladder surgery after a negative urine test?
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
Nanjing, JiangsuAges 18 years+ - NCT07036731Recruiting
Urine test study for second bladder surgery
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Nanjing, JiangsuAges 18–80 - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT06889623Recruiting
Chemotherapy right after surgery for high-risk bladder cancer
This trial tests whether giving chemotherapy immediately after surgery can help people with high-risk, non-muscle-invasive bladder cancer. It aims to reduce the chance of the cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT00913939Recruiting
MRI-guided high-dose-rate treatment for recurrent prostate cancer
This study tests a targeted radiation approach called high-dose-rate (HDR) brachytherapy, guided by MRI, for certain people with recurrent or higher-risk prostate cancer. It may help deliver radiation more precisely, depending on your cancer type and prior treatments.
Toronto, OntarioAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT05037279RecruitingPhase 3
Testing BCG treatment for bladder cancer after full tumor removal
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Vancouver, British ColumbiaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05792722Recruiting
Testing a prostate-sparing bladder surgery for bladder cancer
This trial studies whether a “prostate-sparing” radical cystectomy is safe and effective for bladder cancer patients who are having surgery. It aims to see if this approach can treat bladder cancer while reducing prostate-related side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07369570Recruiting
Watching low-risk prostate lesions with repeat MRI scans
This trial uses repeated MRI scans to monitor prostate lesions that have a low chance of being aggressive cancer. It is for people who have suspicious spots but whose initial biopsies did not find high-grade cancer.
KuopioAges 40 years+ - NCT06822010RecruitingPhase 2
Gemcitabine and Mitomycin for High-Risk Upper Tract Cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and mitomycin, given directly into the kidney or ureter through a thin tube. It is for people with a high-risk but non-invasive form of upper urinary tract cancer that has not spread into deeper tissues.
New Brunswick, New JerseyAges 18–99
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk prostate cancer?
- Yes. Clin2 currently lists 348 recruiting high risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.